Mirvie raises $60 million for pregnancy blood test
The Mirvie RNA platform, the first to predict unforeseen difficulties by disclosing the underlying biology of each pregnancy, will see clinical and commercial development.
Top-tier life science, technology, and financial investors, as well as a maternal health advocate and five-time Olympian Allyson Felix, have contributed to the project.
Following the closing of its Series B investment, Mirvie, a pioneer in forecasting unexpected pregnancy problems, said today that it had raised a total of $90 million so far.
Decheng Capital led the financing, which included contributions from BlackRock, Foresite Capital, General Catalyst, GV, Khosla Ventures, and Mayfield, as well as a debt facility with Comerica Bank. Mirvie will use the funds to continue the clinical and commercial development of its patented Mirvie RNA platform, which is the first to forecast preeclampsia and preterm delivery months before they occur by disclosing each pregnancy’s underlying biology.
“Mirvie is a pathfinder in an area in critical need of innovation to address the frequently fatal and expensive long-term repercussions of pregnancy problems.”
Unexpected problems occur in one out of every five pregnancies, resulting in significant financial expenses and long-term health repercussions for both the expecting parents and their newborns.
In the United States and the European Union alone, they contribute $50 billion in annual healthcare expenses. Women, expectant parents, and doctors, on the other hand, lack a reliable technique to detect difficulties before they manifest symptoms, as well as the resources to grasp their underlying causes.
For the first time in history, the Mirvie RNA platform can identify the specific underlying molecular reasons for previously unknown problems. This innovation has the potential to change how we detect, prevent, and treat pregnancy problems, according to peer-reviewed clinical evidence.
It allows for the customization of existing interventions for patients based on their particular biology, as well as the development of novel interventions that address their specific causes directly.
The Mirvie RNA platform can diagnose 75 percent of women who develop preeclampsia months before symptoms appear, according to a groundbreaking study published in Nature in January 2022. Mirvie is currently working on a test to predict preeclampsia, which has recently been designated as a Breakthrough Device by the US Food and Drug Administration (FDA).
Furthermore, according to a study published in the American Journal of Obstetrics and Gynecology (April 2022), the platform can anticipate 76 percent of early preterm birth cases and identify different molecular pathways that drive their development.
“We believe it unacceptable that pregnancy health has not progressed meaningfully in decades,” stated Maneesh Jain, Mirvie’s Co-Founder and CEO. “We believe the Mirvie RNA platform has the potential to build a new era of predictive, preventative, and individualized prenatal care for millions of expecting parents and newborns.” We’re ecstatic to welcome many top-tier investors who understand the enormous unmet need and have pledged to help us make a difference.”
“Mirvie is a leader in a field in critical need of innovation to address the frequently severe and costly lifetime consequences of pregnancy problems,” stated Min Cui, Ph.D., Founder and Managing Director of Decheng Capital and the funding’s lead investor.
“This financial syndicate is committed to supporting Mirvie’s goal of providing breakthrough innovation to clinicians, expectant parents, and babies that makes what is currently unattainable a reality.”
Allyson Felix, a seven-time Olympic gold winner, and maternal health advocate, joined the fundraising as a new investor. Felix and her daughter survived severe preeclampsia, which culminated in an eight-week-early delivery. She joined the CDC’s Hear Her campaign in March 2021, which aims to raise awareness about life-threatening pregnancy problems.